DFCM
ADCT icon

Dark Forest Capital Management’s ADC Therapeutics ADCT Stock Holding History

Dark Forest Capital Management’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-387
Closed -$8K – 1220
2021
Q4 		$8K Sell
387
-536
-58% -$12.9K ﹤0.01% 994
2021
Q3 		$25K Buy
+923
New +$23.6K 0.01% 745

Other funds holding ADCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
VCG
Vantage Consulting Group Virginia Beach, Virginia $19.7M AUM 280.87% 1-Year Est. Return
GH
Grosvenor Holdings Chicago, Illinois $512M AUM 19.57% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Dark Forest Capital Management's ADCT Position: Q1 2022 in Review

Dark Forest Capital Management sold out of ADC Therapeutics (ADCT) in Q1 2022, closing a stake of 387 shares — an estimated $8K sold.

Dark Forest Capital Management first reported a position in ADCT in Q3 2021 and held it in 2 quarters. The position peaked at $25K in Q3 2021. 49 funds tracked by Wall St. Rank hold ADCT as of Q1 2022.

  • Dark Forest Capital Management reported no remaining ADC Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Dark Forest Capital Management sold 387 ADC Therapeutics shares in Q1 2022, an estimated $8K.
  • Dark Forest Capital Management first reported a position in ADC Therapeutics in Q3 2021 and held it in 2 quarters.
  • Dark Forest Capital Management's ADC Therapeutics position peaked at $25K in Q3 2021.
  • 49 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2022.

Based on Dark Forest Capital Management's 13F filing for Q1 2022, filed 13 May 2022.